NEW YORK (TheStreet) -- Alcobra (ADHD) shares are down -2.81% to $20.03 on Wednesday after having coverage initiated with a "market perform" rating and $23 price target by analysts at FBR Capital Markets.

The Israel-based biopharmaceutical company is in the process of developing a drug treatment for Attention Deficit Hyperactivity Disorder.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title


data by


EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.